InvestorsObserver is giving Vir Biotechnology Inc (VIR) an Analyst Rating Rank of 32, meaning VIR is ranked higher by analysts than 32% of stocks. The average price target for VIR is $46.833 and analyst’s rate the stock as a Buy.
Why are Analyst Ratings Important?
A company’s financial statements are a significant factor weighted by experts when analyzing a company’s health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What’s Happening With Vir Biotechnology Inc Stock Today?
Vir Biotechnology Inc (VIR) stock has fallen -1.97% while the S&P 500 has risen 0.45% as of 1:29 PM on Tuesday, Oct 11. VIR has fallen -$0.42 from the previous closing price of $21.28 on volume of 335,473 shares. Over the past year the S&P 500 is lower by -16.80% while VIR has fallen -47.88%. VIR earned $8.03 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 2.6.
Click Here to get the full Stock Report for Vir Biotechnology Inc stock.
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Originally published at Melbourne News Vine
No comments:
Post a Comment